Description
Blood, NA, Fasting or Non Fasting: As suggested by doctor
Sample Required:
The sample required for the IHC Single Marker (Her2 Neu) Test is typically a tissue biopsy specimen. This specimen is collected from the patient and is commonly obtained during procedures such as a breast biopsy.
Test Time:
The test time can vary depending on the laboratory’s processing time and the complexity of the case. Results may be available in a few days to a couple of weeks.
Test Normal Range:
The IHC Single Marker (Her2 Neu) Test does not have a “normal range” like some blood tests. Instead, it assesses the presence or absence of human epidermal growth factor receptor 2 (Her2 Neu) proteins within tissue samples.
What is the Test?
The IHC Single Marker (Her2 Neu) Test is a specialized immunohistochemistry (IHC) laboratory test used to detect and visualize human epidermal growth factor receptor 2 (Her2 Neu) proteins within tissue samples. It is commonly utilized in breast cancer diagnosis and treatment planning. The test helps determine whether the cancer cells in a breast tumor overexpress Her2 Neu receptors.
Test Procedure:
A tissue biopsy sample, often from a breast tumor, is collected from the patient.The tissue sample is processed, embedded in paraffin wax, and cut into thin sections.These sections are placed on slides and treated with specific antibodies that bind to Her2 Neu proteins. Chemical reactions are used to visualize the binding of antibodies to Her2 Neu proteins. The tissue sections are examined under a microscope to assess the presence and distribution of Her2 Neu receptors.
When to Take the Test:
The IHC Single Marker (Her2 Neu) Test is typically ordered by a healthcare provider when a patient has a breast biopsy or tissue sample from another site that needs further examination. It helps guide treatment decisions for breast cancer.
Who Should Take This Test:
Patients with breast tumors or suspected breast cancer may have this test performed if their healthcare provider believes it is necessary for diagnosis or treatment planning.
Precautions for Exceptional Cases:
In exceptional cases, such as pregnancy, the decision to perform the IHC Single Marker (Her2 Neu) Test will depend on the specific medical situation and the recommendations of the healthcare provider. It’s essential to discuss any concerns or potential risks with the healthcare team.
FAQs (Frequently Asked Questions):
Q1: What does a positive Her2 Neu result mean in breast cancer testing?
A: A positive result indicates that there is an overexpression of Her2 Neu receptors on the cancer cells. This may suggest that targeted therapies, such as Her2-targeted drugs, could be suitable treatment options.
Q2: What if my breast cancer is Her2-negative?
A: An Her2-negative result means that there is no overexpression of Her2 Neu receptors on the cancer cells. In this case, Her2-targeted therapies may not be effective, and other treatment options will be considered.
Q3: Are there any risks associated with the IHC Single Marker (Her2 Neu) Test?
A: The test itself is low-risk. However, there may be risks associated with the biopsy or surgical procedure used to collect the tissue sample, which should be discussed with the healthcare provider.
Q4: Can this test definitively diagnose breast cancer?
A: While the IHC Single Marker (Her2 Neu) Test is an essential component of breast cancer diagnosis and treatment planning, a definitive diagnosis often requires a combination of tests, including histopathology, imaging, and clinical assessment.
Q5: How do I prepare for the IHC Single Marker (Her2 Neu) Test?
A: Preparation typically involves discussing the procedure with your healthcare provider and following any pre-test instructions they provide. This may include fasting before the biopsy procedure or discontinuing certain medications temporarily.
